Julian Brody represents public and private companies on corporate and securities law matters, including disclosure, corporate governance, and SEC compliance.

Julian also advises companies and underwriters on a variety of capital markets transactions, with a focus on initial public offerings, secondary and follow-on offerings, at-the-market offerings, high-yield and investment-grade debt offerings, convertible debt offerings and other capital-raising transactions. His public company clients include US Nasdaq and New York Stock Exchange-listed companies across a broad range of industries, including life sciences, technology, REITs and energy.

Julian has experience in a variety of industries, including life sciences, technology, REIT and energy. His experience includes representing:

Life Sciences

  • Avidity Biosciences in its US$200.0m at-the-market offering
  • Bionomics in its US$20.0m IPO
  • CG Oncology in its US$204.4m IPO
  • Gritstone Bio in its US$32.5m follow-on offering, US$45.0m PIPE financing and US$100m at-the-market offering
  • HilleVax in its US$100.0m IPO
  • Icosavax in its US$182.0m IPO
  • Orbital Therapeutics in its US$270.0m Series A preferred stock financing
  • The underwriters in CG Oncology’s US$204.4m follow-on offering
  • The underwriters in Janux Therapeutics’ US$222.0m IPO and US$350.0m follow-on offering
  • The agent in Janux Therapeutics’ US$150.0m at-the-market offering
  • The underwriters in ImmunoGen’s US$325.0m follow-on offering
  • The underwriters in Immunome’s US$150.0m and US$200.0m follow-on offerings
  • The underwriters and the agent in Nyxoah’s US$49.7m follow-on offering and US$50.0m at-the-market offering
  • The underwriters and the placement agents in Structure Therapeutics’ US$185.3m IPO, US$300.0m PIPE financing and US$476.0m follow-on offering
  • The underwriters in Travere Therapeutics’ US$125.0m follow-on offering

Technology

  • Alkami Technology in the following transactions: 
    • US$300.0m convertible notes offering
    • US $281.3m secondary offering
    • US$155.9m secondary offering
  • Health Catalyst’s US$225.0m follow-on offering
  • High Trail Capital, an investment fund, in the purchase of US$69.0m of convertible notes of MicroVision
  • Nextiva in its US$200.0m convertible preferred stock financing
  • The underwriters in GlobalFoundries’ $950.0m follow-on offering
  • The underwriters in LegalZoom’s US$535.0m IPO
  • The underwriters in Snap One Holdings’ US$249.3m IPO

REIT

  • American Assets Trust in its US$525.0m senior notes offering and its US$250.0m at-the-market offering
  • Essex Property Trust in its aggregate US$550.0m senior notes offering
  • Extra Space Storage in its US$400.0m senior notes offering

Energy 

  • Sempra in various notes offerings and at-the-market offerings, raising more than US$7.6b
  • San Diego Gas & Electric in various bond offerings, raising more than US$1.5b
  • Southern California Gas in various bond offerings, raising more than US$2.2b
  •  High Trail Capital, an investment fund, in the following transactions:
    • Purchase of US$142.25 million Series F Convertible Preferred Shares of Prairie Operating Co.
    • Purchase of US$500.0 million senior convertible note of Tellurian 

Bar Qualification

  • California

Education

  • J.D., University of Michigan Law School, 2013
    cum laude
  • B.A., Hamilton College, 2010
Badges and Logos_Law360_Fintech Group of the Year_2024
February 20, 2025 Recognition

Fintech Group of the Year: Latham

Firm honored by Law360 for advising startups, financial institutions, VCs, digital asset and Web3 participants, and corporations on their most innovative and complex transactions, investigations, litigation, and regulatory matters.